Clinical trial
Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant…
NCT00081536 · Aronex Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00081536 |
|---|---|
| Title | Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies |
| Official title | A Phase I/II Study of Aroplatin and Capecitabine in Subjects With Unresectable Local Recurrence or Distant Metastases of Colorectal Cancer Refractory to 5-FU/Leucovorin and Irinotecan |
| Lead sponsor | Aronex Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Drug |
| Interventions | Aroplatin (Liposomal NDDP) in combination with capecitabine |
| Enrollment | 105 |
| First posted | Apr 20, 2004 |
| Last update posted | Jun 24, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: